Clinical evaluation of mendelian hypertensive and hypotensive disorders

Seminars in Nephrology

Volumn 30, Issue 4, 2010, Pages 387-394

  Geller, David S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Genetics; Hypertension; Sodium transport; Tubular disorders

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMILORIDE; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CORTICOTROPIN; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPITHELIAL SODIUM CHANNEL; GLYCYRRHIZIC ACID; HYDROCHLOROTHIAZIDE; HYDROCORTISONE; MINERALOCORTICOID RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM; POTASSIUM CHANNEL; POTASSIUM CHLORIDE; SODIUM; SODIUM CHANNEL BLOCKING AGENT; SODIUM CHLORIDE COTRANSPORTER; SODIUM POTASSIUM CHLORIDE COTRANSPORTER; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

APPARENT MINERALOCORTICOID EXCESS SYNDROME; ARTICLE; BARTTER SYNDROME; CLINICAL ASSESSMENT; DIAGNOSTIC VALUE; GENETIC SCREENING; GITELMAN SYNDROME; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; HYPOKALEMIC ALKALOSIS; HYPOTENSION; KIDNEY TRANSPLANTATION; LIDDLE SYNDROME; MATERNAL HYPERTENSION; PRIORITY JOURNAL; PSEUDOHYPOALDOSTERONISM; SENSITIVITY AND SPECIFICITY;

GENETIC TESTING; HUMANS; HYPERTENSION; HYPOTENSION; PHENOTYPE; RENAL TUBULAR TRANSPORT, INBORN ERRORS;

EID: 77956161522     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2010.06.005     Document Type: Article

References (27)

1. Lifton R.P., Dluhy R.G., Powers M., Rich G.M., Cook S., Ulick S., et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992, 355:262-265.
2. Mantero F., Mattarello M.J., Albiger N.M. Detecting and treating primary aldosteronism: primary aldosteronism. Exp Clin Endocrinol Diabetes 2007, 115:171-174.
3. Dluhy R.G., Anderson B., Harlin B., Ingelfinger J., Lifton R. Glucocorticoid-remediable aldosteronism is associated with severe hypertension in early childhood. J Pediatr 2001, 138:715-720.
4. Litchfield W.R., New M.I., Coolidge C., Lifton R.P., Dluhy R.G. Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1997, 82:3570-3573.
5. Jeunemaitre X., Bassilana F., Persu A., Dumont C., Champigny G., Lazdunski M., et al. Genotype-phenotype analysis of a newly discovered family with Liddle's syndrome. J Hypertens 1997, 15:1091-1100.
6. Botero-Velez M., Curtis J.J., Warnock D.G. Brief report: Liddle's syndrome revisited - a disorder of sodium reabsorption in the distal tubule. N Engl J Med 1994, 330:178-181.
7. Mune T., Rogerson F.M., Nikkila H., Agarwal A.K., White P.C. Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. Nat Genet 1995, 10:394-399.
8. Dave-Sharma S., Wilson R.C., Harbison M.D., Newfield R., Azar M.R., Krozowski Z.S., et al. Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab 1998, 83:2244-2254.
9. Geller D.S., Farhi A., Pinkerton N., Fradley M., Moritz M., Spitzer A., et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000, 289:119-123.
10. Mayan H., Vered I., Mouallem M., Tzadok-Witkon M., Pauzner R., Farfel Z. Pseudohypoaldosteronism type II: marked sensitivity to thiazides, hypercalciuria, normomagnesemia, and low bone mineral density. J Clin Endocrinol Metab 2002, 87:3248-3254.
11. Throckmorton D.C., Bia M.J. Pseudohypoaldosteronism: case report and discussion of the syndrome. Yale J Biol Med 1991, 64:247-254.
12. Gereda J.E., Bonilla-Felix M., Kalil B., Dewitt S.J. Neonatal presentation of Gordon syndrome. J Pediatr 1996, 129:615-617.
13. Hanukoglu A. Type I pseudohypoaldosteronism includes two clinically and genetically distinct entities with either renal or multiple target organ defects. J Clin Endocrinol Metab 1991, 73:936-944.
14. Kerem E., Bistritzer T., Hanukoglu A., Hofmann T., Zhou Z., Bennett W., et al. Pulmonary epithelial sodium-channel dysfunction and excess airway liquid in pseudohypoaldosteronism. N Engl J Med 1999, 341:156-162.
15. Geller D.S., Rodriguez-Soriano J., Vallo Boado A., Schifter S., Bayer M., Chang S.S., et al. Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism type I. Nat Genet 1998, 19:279-281.
16. Geller D.S., Zhang J., Zennaro C.M., Rodriguez-Soriano J., Vallo Boado A., Rayniere S., et al. Autosomal dominant pseudohypoaldosteronism type 1: mechanisms, evidence for neonatal lethality, and phenotypic expression in adults. J Am Soc Nephrol 2006, 17:1429-1436.
17. Simon D.B., Karet F.E., Hamdan J.M., DiPietro A., Sanjad S.A., Lifton R.P. Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat Genet 1996, 13:183-188.
18. Simon D.B., Karet F.E., Rodriguez-Soriano J., Hamdan J.H., DiPietro A., Trachtman H., et al. Genetic heterogeneity of Bartter's syndrome revealed by mutations in the K+ channel, ROMK. Nat Genet 1996, 14:152-156.
19. Simon D.B., Bindra R.S., Mansfield T.A., Nelson-Williams C., Mendonca E., Stone R., et al. Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III. Nat Genet 1997, 17:171-178.
20. Fukuyama S., Hiramatsu M., Akagi M., Higa M., Ohta T. Novel mutations of the chloride channel Kb gene in two Japanese patients clinically diagnosed as Bartter syndrome with hypocalciuria. J Clin Endocrinol Metab 2004, 89:5847-5850.
21. Birkenhager R., Otto E., Schurmann M.J., Vollmer M., Ruf E.M., Maier-Lutz I., et al. Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. Nat Genet 2001, 29:310-314.
22. Schlingmann K.P., Konrad M., Jeck N., Waldegger P., Reinalter S.C., Holder M., et al. Salt wasting and deafness resulting from mutations in two chloride channels. N Engl J Med 2004, 350:1314-1319.
23. Pollak M.R., Chou Y.H., Marx S.J., Steinmann B., Cole D.E., Brandi M.L., et al. Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Effects of mutant gene dosage on phenotype. J Clin Invest 1994, 93:1108-1112.
24. Watanabe S., Fukumoto S., Chang H., Takeuchi Y., Hasegawa Y., Okazaki R., et al. Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. Lancet 2002, 360:692-694.
25. Gitelman H.J., Graham J.B., Welt L.G. A new familial disorder characterized by hypokalemia and hypomagnesemia. Trans Assoc Am Physicians 1966, 79:221-235.
26. Simon D.B., Nelson-Williams C., Bia M.J., Ellison D., Karet F.E., Molina A.M., et al. Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet 1996, 12:24-30.
27. Cruz D.N., Shaer A.J., Bia M.J., Lifton R.P., Simon D.B. Gitelman's syndrome revisited: an evaluation of symptoms and health-related quality of life. Kidney Int 2001, 59:710-717.